OPERA

In OPERA, the rate of retention in care in people receiving CABENUVA or daily oral therapy:*

*HIV retention in care is defined as 2 or more viral load or CD4 tests per year, 3 or more months apart.

OPERA is an observational cohort that collects routine clinical data from electronic health records in the US. This analysis includes virologically suppressed adults initiating CABENUVA or a new oral ART regimen between 1/21/2021 and 6/30/2022. CABENUVA recipients were matched to up to 3 oral ART recipients based on age, sex, and location.

These results are descriptive in nature and should not be used to infer clinical significance.

Desired by patients in a clinical trial

See VOLITION data

ART=antiretroviral therapy; IQR=interquartile range.

Reference:

  1. Lackey PC, Palmieri Weber R, Pierone G Jr. Increased screening for sexually transmitted infections and HIV surrogate marker testing among long-acting injectable versus daily oral ART antiretroviral therapy users in the OPERA cohort. Poster presented at: AIDS 2024, July 22-26, 2024, Munich, Germany. WEPEC319.

PMUS-CBRWCNT250026